1. Home
  2. IDE vs OBIO Comparison

IDE vs OBIO Comparison

Compare IDE & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Voya Infrastructure Industrials and Materials Fund of Beneficial Interest

IDE

Voya Infrastructure Industrials and Materials Fund of Beneficial Interest

HOLD

Current Price

$13.87

Market Cap

205.1M

Sector

Finance

ML Signal

HOLD

Logo Orchestra BioMed Holdings Inc.

OBIO

Orchestra BioMed Holdings Inc.

HOLD

Current Price

$4.09

Market Cap

237.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IDE
OBIO
Founded
2010
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
205.1M
237.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
IDE
OBIO
Price
$13.87
$4.09
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$14.25
AVG Volume (30 Days)
33.5K
201.0K
Earning Date
01-01-0001
03-30-2026
Dividend Yield
8.83%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,818,000.00
Revenue This Year
N/A
$36.66
Revenue Next Year
N/A
$2.30
P/E Ratio
N/A
N/A
Revenue Growth
N/A
6.46
52 Week Low
$8.61
$2.20
52 Week High
$10.46
$5.98

Technical Indicators

Market Signals
Indicator
IDE
OBIO
Relative Strength Index (RSI) 80.00 49.19
Support Level $13.23 $3.62
Resistance Level $13.52 $4.25
Average True Range (ATR) 0.15 0.34
MACD 0.01 0.03
Stochastic Oscillator 87.39 63.74

Price Performance

Historical Comparison
IDE
OBIO

About IDE Voya Infrastructure Industrials and Materials Fund of Beneficial Interest

Voya Infrastructure, Industrials and Materials Fund is a diversified closed-end management investment company. The primary objective of this investment fund is to achieve total return by combining current income, capital gains, and capital appreciation. To achieve this objective, the fund invests in companies that own and/or operate infrastructure facilities in the infrastructure sector, as well as in a broad range of companies in the industrials and materials sectors that the Sub-Adviser believes will benefit from infrastructure building, renovation, expansion, and utilization.

About OBIO Orchestra BioMed Holdings Inc.

Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.

Share on Social Networks: